BR9910793A - Preparação de liberação controlada que tem estrutura em multicamada - Google Patents

Preparação de liberação controlada que tem estrutura em multicamada

Info

Publication number
BR9910793A
BR9910793A BR9910793-7A BR9910793A BR9910793A BR 9910793 A BR9910793 A BR 9910793A BR 9910793 A BR9910793 A BR 9910793A BR 9910793 A BR9910793 A BR 9910793A
Authority
BR
Brazil
Prior art keywords
controlled release
multilayer structure
degradable
drugs
dispersed
Prior art date
Application number
BR9910793-7A
Other languages
English (en)
Other versions
BR9910793B1 (pt
Inventor
Akihiko Sano
Masako Kajihara
Toshihiko Sugie
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Publication of BR9910793A publication Critical patent/BR9910793A/pt
Publication of BR9910793B1 publication Critical patent/BR9910793B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Patente de Invenção: <B>"PREPARAçãO DE LIBERAçãO CONTROLADA QUE TEM ESTRUTURA EM MULTICAMADA"<D>. Preparações em que duas ou mais drogas podem ser liberadas separadamente a velocidades apropriadas dependendo da doença ou dos comportamentos de liberação de uma ou mais drogas podem ser controladas com precisão, que consiste em uma camada externa em que uma droga solúvel em água é dispersa em um veículo obtido de um material polímero hidrófobo biologicamente não-degradável e uma ou mais camadas internas em que uma droga solúvel em água, que difere em espécie ou em concentração de uma contida na camada externa, é dispersa em um veículo obtido de um material polímero hidrófobo biologicamente não-degradável e em que as camadas externa e interna estão localizadas concentricamente em direção diametral de preparações semelhantes a bastão e ambas ou uma das extremidades na direção axial está aberta de modo a entrar diretamente em contato com o ambiente.
BRPI9910793-7A 1998-05-29 1999-05-19 composiÇço farmacÊutica implantÁvel em forma de bastço de liberaÇço controlada que tem estrutura em multicamada. BR9910793B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14859198 1998-05-29
PCT/JP1999/002594 WO1999062501A1 (fr) 1998-05-29 1999-05-19 Preparations de liberation controlee a structure multicouche

Publications (2)

Publication Number Publication Date
BR9910793A true BR9910793A (pt) 2001-02-13
BR9910793B1 BR9910793B1 (pt) 2010-12-14

Family

ID=15456186

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9910793-7A BR9910793B1 (pt) 1998-05-29 1999-05-19 composiÇço farmacÊutica implantÁvel em forma de bastço de liberaÇço controlada que tem estrutura em multicamada.

Country Status (17)

Country Link
US (1) US7101567B1 (pt)
EP (1) EP1084703B1 (pt)
JP (1) JP4459444B2 (pt)
KR (1) KR100584632B1 (pt)
CN (1) CN1165294C (pt)
AT (1) ATE300939T1 (pt)
AU (1) AU752952B2 (pt)
BR (1) BR9910793B1 (pt)
CA (1) CA2333555C (pt)
DE (1) DE69926504T2 (pt)
DK (1) DK1084703T3 (pt)
ES (1) ES2245827T3 (pt)
NZ (1) NZ508400A (pt)
PT (1) PT1084703E (pt)
TW (1) TW586944B (pt)
WO (1) WO1999062501A1 (pt)
ZA (1) ZA200006829B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100402053B1 (ko) * 2000-09-28 2003-10-17 한국화학연구원 항생제의 서방성 임플란트 제제
BR0115392A (pt) * 2000-11-03 2004-06-15 Biomedicines Inc Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
EP1250933A1 (en) * 2001-04-17 2002-10-23 Istituto Superiore di Sanità Vaccines including as an adjuvant high dose type I IFN
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
CN100556762C (zh) * 2002-02-13 2009-11-04 迈克尔K·韦伯尔 药物剂型及其制造方法
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040249364A1 (en) * 2003-06-03 2004-12-09 Ilya Kaploun Device and method for dispensing medication to tissue lining a body cavity
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8394391B2 (en) * 2007-08-31 2013-03-12 University Of Utah Research Foundation Drug delivery vehicle that mimics viral properties
TW200930343A (en) 2007-09-21 2009-07-16 Organon Nv Drug delivery system
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068235A1 (en) * 2008-09-16 2010-03-18 Searete LLC, a limited liability corporation of Deleware Individualizable dosage form
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US8753677B2 (en) * 2008-09-16 2014-06-17 The Invention Science Fund I, Llc Ex vivo modifiable multiple medicament final dosage form
US20100068152A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo modifiable particle or polymeric based final dosage form
US20100068254A1 (en) * 2008-09-16 2010-03-18 Mahalaxmi Gita Bangera Modifying a medicament availability state of a final dosage form
CN105726201B (zh) * 2009-05-18 2020-08-25 多斯医学公司 给药眼植入物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011037953A2 (en) * 2009-09-22 2011-03-31 Surmodics Pharmaceuticals, Inc. Implant devices having varying bioactive agent loading configurations
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
EP2547332B1 (en) * 2010-03-16 2018-08-29 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013030267A1 (en) * 2011-08-30 2013-03-07 Universiteit Gent Multi-layered release formulation
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3302354B1 (en) 2015-06-03 2023-10-04 i2o Therapeutics, Inc. Implant placement systems
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN110538158A (zh) * 2019-09-10 2019-12-06 郑州百瑞动物药业有限公司 一种水产用长效缓释双层片状消毒剂及其制备方法
CN114699512B (zh) * 2022-04-02 2024-05-28 贵州医科大学 一种甲状旁腺激素缓释药物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4191741A (en) * 1978-09-22 1980-03-04 Eli Lilly And Company Removable drug implant
US4601893A (en) * 1984-02-08 1986-07-22 Pfizer Inc. Laminate device for controlled and prolonged release of substances to an ambient environment and method of use
JPH0761959B2 (ja) * 1985-10-11 1995-07-05 住友製薬株式会社 シリコンエラストマ−系徐放性製剤
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
EP0230654B1 (en) * 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4846844A (en) * 1987-08-31 1989-07-11 Eli Lilly And Company Antimicrobial coated implants
JP3118009B2 (ja) * 1991-04-16 2000-12-18 住友製薬株式会社 多層構造を有するコラーゲンおよび／またはゼラチン製剤の製造方法
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
FR2729539B1 (fr) 1995-01-23 1997-04-11 Virbac Lab Dispositif a liberation controlee de substances chimiques, destine a etre fixe sur un animal et procede de preparation dudit dispositif
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ

Also Published As

Publication number Publication date
ZA200006829B (en) 2001-09-04
TW586944B (en) 2004-05-11
JP4459444B2 (ja) 2010-04-28
ES2245827T3 (es) 2006-01-16
AU3848799A (en) 1999-12-20
CN1303277A (zh) 2001-07-11
KR20010043683A (ko) 2001-05-25
WO1999062501A1 (fr) 1999-12-09
CA2333555C (en) 2008-02-26
CN1165294C (zh) 2004-09-08
DK1084703T3 (da) 2005-08-29
EP1084703B1 (en) 2005-08-03
PT1084703E (pt) 2005-11-30
ATE300939T1 (de) 2005-08-15
CA2333555A1 (en) 1999-12-09
EP1084703A4 (en) 2002-04-03
DE69926504T2 (de) 2006-06-08
DE69926504D1 (de) 2005-09-08
KR100584632B1 (ko) 2006-05-30
BR9910793B1 (pt) 2010-12-14
NZ508400A (en) 2002-10-25
AU752952B2 (en) 2002-10-03
US7101567B1 (en) 2006-09-05
EP1084703A1 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
BR9910793A (pt) Preparação de liberação controlada que tem estrutura em multicamada
DE69811278D1 (de) Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
PT644771E (pt) Sistema de entrega da droga eritropoietina
DE3865631D1 (de) Darreichungsform mit kontrollierter freigabe.
DE69935605D1 (de) Ladung und abgabe von wasser unlöslicher arzneimittel
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
UY26352A1 (es) Método para aumentar la actividad en mascotas
TR199801889T2 (xx) Gradyanl� nefes alabilme kabiliyetini havi emici e�ya.
ATE77931T1 (de) Anwendung von mikrokapseln zur herstellung einer aus elastomeren bestehenden prophylaxevorrichtung, wie eines praeservativs oder dergleichen, und ihr herstellungsverfahren.
WO2000033820A3 (de) Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen
KR920703071A (ko) 지질 저하제로서 콜레스티라민을 함유하는 미세정제
BR0200247A (pt) Mancal de rolamento linear de intertravamento
AR009696A2 (es) Dispositivo inhalador para administrar un polvo seco medicamentoso, procedimiento para su realizacion y envase de burbujas para ser usado con dicho dispositivo.
DE69800046D1 (de) Gepresster Käfig und Kugellager mit dem gepressten Käfig
ES2170791T3 (es) Productos sanitarios delgados con cuerpo absorbente prefabricado.
DK1112739T3 (da) Langtidsafgivende depot-præparat
KR900012622A (ko) 피부질환치료 조성물
KR910017098A (ko) 방진(防振) 고무
KR900000640A (ko) 실린더 정지장치
Glesby Interpreting HIV clinical trials
KR910000147A (ko) 항 궤양 치료제
KR920021889A (ko) 등속자재조인트

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DAINIPPON PHARMACEUTICAL CO., LTD (JP)

Free format text: TRANSFERIDO DE: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

B25D Requested change of name of applicant approved

Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD. (JP)

Free format text: ALTERADO DE: DAINIPPON PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/12/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2309 DE 07-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.